Fusion Q1 net loss $33.7M; AstraZeneca acquisition on track for Q2 2024

Fusion Pharmaceuticals Inc.

2024-Q1 EPS reported -$0.40

Net loss of $33.7M ($0.40/sh) vs $24.3M ($0.45/sh) in Q1 2023; R&D spend $21.3M.
Cash and investments $283.1M as of March 31, 2024; expected to fund operations into Q4 2025.
Definitive agreement to be acquired by AstraZeneca for up to $2.4B ($21/sh cash + $3 CVR); HSR clearance and Canadian Competition Bureau no-action received; expected close Q2 2024.
Interim data for FPI-2265 in mCRPC presented at AACR 2024; Phase 2 dose optimization trial to start Q2 2024, Phase 3 registrational trial planned for 2025.
FPI-1434 Phase 1 trial shows encouraging early findings; no DLTs in 25 kBq/kg cohort; stable disease and anti-tumor activity observed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Fusion Pharmaceuticals Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 7, 2024, Fusion Pharmaceuticals Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2024.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-053948

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.